Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy

Josè Manuel Pioner1*, Alessandra Fornaro2, Raffaele Coppini2, Nicole Ceschi2, Leonardo Sacconi1, Maria Alice Donati5, Silvia Favilli6, Corrado Poggesi1, Iacopo Olivotto2 and Cecilia Ferrantini1

1 Division of Physiology, Department of Experimental and Clinical Medicine, Università degli Studi di Firenze, Florence, Italy, 2 Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy, 3 Department of NeuroFarBa, Università degli Studi di Firenze, Florence, Italy, 4 LENS, Università degli Studi di Firenze and National Institute of Optics (INO-CNR), Florence, Italy, 5 Metabolic Unit, A. Meyer Children’s Hospital, Florence, Italy, 6 Pediatric Cardiology, Meyer Children’s Hospital, Florence, Italy

Familial dilated cardiomyopathy (DCM) is mostly caused by mutations in genes encoding cytoskeletal and sarcomeric proteins. In the pediatric population, DCM is the predominant type of primitive myocardial disease. A severe form of DCM is associated with mutations in the DMD gene encoding dystrophin, which are the cause of Duchenne Muscular Dystrophy (DMD). DMD-associated cardiomyopathy is still poorly understood and orphan of a specific therapy. In the last 5 years, a rise of interest in disease models using human induced pluripotent stem cells (hiPSCs) has led to more than 50 original studies on DCM models. In this review paper, we provide a comprehensive overview on the advances in DCM cardiomyopathy disease modeling and highlight the most remarkable findings obtained from cardiomyocytes differentiated from hiPSCs of DMD patients. We will also describe how hiPSCs based studies have contributed to the identification of specific myocardial disease mechanisms that may be relevant in the pathogenesis of DCM, representing novel potential therapeutic targets.

Keywords: dilated cardiomyopathy (DCM), duchenne muscular dystrophy (DMD), dystrophin (DMD), hiPSC-cardiomyocyte, stem cell models

Abbreviations: AAV, Adeno-associated virus; ABCG9, Sulfonylurea receptor 2A, component of ATP-sensitive potassium channel; AB1, actin-binding domain; ACTC1, α-cardiac actin; ACTN2, β-actin; AF, atrial fibrillation; ANKRD1, Cardiac ankyrin repeat protein; ARVC, arrhythmogenic right ventricular cardiomyopathy; BAG3, BCL2-associated athanogene 3; BMD, Becker Muscular Dystrophy; CM, Cardiomyocytes; CMR, cardiac magnetic resonance; CRISPR-Cas9, Clustered Regularly Interspaced Short Palindromic Repeats; CRYAB, α-B-crystallin; CSP3, Muscle LIM protein; DCM, Dilated cardiomyopathy; DES, Desmin; DGC, dystrophin glycoproteic complex; DMD, Duchenne Muscular Dystrophy; DMD, dystrophin gene; DNAJC19, HSP40 homolog, C19; C19, Dp427, Full-length dystrophin isoform (427 kDa); Dp71, Dystrophin isoform (71 kDa); DSP, Desmoplakin; ECG, electrocardiogram; EHT, engineered heart tissue; EMD, Emerin; fast k_EFF, fast phase of myofibril relaxation; FLNC, Filamin C; HCM, hypertrophic cardiomyopathy; HF, Heart failure; hiPSC, Human induced pluripotent stem cell; HT, heart transplantation; ICD, implantable cardioverter defibrillators; k_sc, myofibril kinetic of force development; KCNQ1, Potassium channel; LDB3, Cipher/ZASP; LMNA, Lamin A/C; LQT, long QT syndrome; LV, left ventricle; LVEF, left ventricular ejection fraction; LVNC, left ventricular non-compaction; MF, myocardial fibrosis; MYH7, β-Myosin heavy chain; NELL1, Nebulette; nNOS, nitric oxide synthase; OMT, optimal medical therapy; PM, protoscaler adjacent motif; PLN, Phospholamban; PMO, phosphorodiamidate morpholino oligomer; RBM20, RNA-binding protein 20; RCM, restrictive cardiomyopathy; RCT, randomized control trial; SCD, sudden cardiac death; SCN5A, Type V voltage-gated cardiac Na channel; SGCA, SGCB, SGCD, α/-,/-,-Sarcoglycan; slow k_EFF, slow linear phase of myofibril relaxation; TALEN, transcription activator-like effector nucleases; TAZ/G4.5, Tafazzin; TCFP, Titin-cap/telethonin; TN1C1, Cardiac troponin C; TN1C3, Cardiac troponin I; TN1C3K, Troponin I-interactive kinase; TNNT2, Cardiac troponin T; TPM1, α-Tropomyosin; TTN, Titin; VGZ, Metavinculin; VE, ventricular fibrillation; VT, ventricular tachycardia.
HIGHLIGHTS

- Mutations in the DMD gene (encoding dystrophin) account for 2% of inherited dilated cardiomyopathy (DCM). Advances in in vitro disease modeling using induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) may help develop specific therapies aimed at restoring or blunting myocardial damage and dysfunction in Duchenne and Becker Muscular Dystrophy.

- This review focuses on the physiological role of dystrophin in cardiomyocyte function during cardiac development and disease progression. The pathological mechanisms caused by the absence of dystrophin or the presence of truncated dystrophin isoforms are discussed. We provide an overview of the most recent and remarkable results obtained using hiPSC-CM lines with DMD mutations.

- Many studies employed hiPSC-CMs for pilot tests of gene therapy strategies. In vitro models such as DMD patient-cardiomyocytes offers a limitless source of human tissue to explore novel disease mechanisms that may represent targets for pharmacological intervention, tested and validated using novel high-throughput cell-screening techniques. Dystrophin-associated cardiomyopathy is an example of a rare cardiac disease where stem cell-based disease-modeling may help developing truly “patient-specific” therapeutic strategies.

Mutations in the dystrophin gene at the Xp21.1 locus are associated with devastating X-linked skeletal muscle disorders, such as Duchenne or Becker muscular dystrophies (DMD/BMD), and account for <2% of dilated cardiomyopathy (DCM) cases. The incidence of DMD is 1/5,000 male births (Mendell et al., 2012). Despite its low prevalence (<3/10,000), dystrophin-associated cardiomyopathy is the form of DCM that has been modeled in vitro more extensively using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from patients. As a case in point, twenty original studies based on the use of DMD/BMD iPSC-derived cell lines are present in the recent literature (2015–2019), as opposed to only few isolated examples for other genetically determined DCMs (Table 1). Why is dystrophin-associated cardiomyopathy more widely studied in vitro compared to other forms of DCM? And are DMD/BMD in vitro models specific in recapitulating dystrophin-related pathophysiology, or can lessons be learned regarding the wider spectrum of DCM?

The first answer is simple: an intense and growing interest in DMD/BMD models derives from its potential for gene therapy. Given the severity of skeletal muscle damage associated with dystrophin depletion, a number of gene-targeted therapies aimed at inducing dystrophin expression have been developed. These promising gene-editing approaches have been developed for DMD to a level far beyond what has been achieved for any other cardiac or skeletal muscle diseases. Gene-editing strategies are being thoroughly evaluated in vitro in hopes of improving/delaying cardiac as well as muscular involvement in DMD patients.

The second issue is far more challenging and largely unresolved. Lack of dystrophin and of its stabilizing effects on the cytoskeleton causes a variety of downstream pathogenic mechanisms, ultimately leading to calcium dysregulation and sarcomere dysfunction. Whether and how all or part of these pathways are relevant to other forms of genetically-driven or acquired DCM, remains to be studied. In light of the advancements introduced by iPSC-derived cardiomyocyte modeling, the present review aims to describe the principal pathophysiological mechanisms associated with DMD, with the purpose of defining to what extent these mechanisms are specific to dystrophin depletion or rather, they are part of the wider spectrum of DCM-related cardiac abnormalities. Finally, we will discuss their implications for therapeutic discovery and tailored patient management.

THE EMERGING SPECTRUM OF GENETIC DCM

DCM is a disease of the myocardium characterized by left ventricular (LV) dilatation and dysfunction with an estimated prevalence of 1:2,500, an incidence of 7:100,000 and a male to female ratio of 3:1, in adults (Rakar et al., 1997). Recent estimates suggest a considerably higher prevalence of ≥1 in 250 individuals (Hershberger et al., 2013). In the pediatric population, DCM is the predominant type of cardiomyopathy and its incidence is higher in the first year of life (Lipshultz et al., 2003). DCM is one of the leading causes of heart failure (HF) and the most frequent indication for heart transplantation (Japp et al., 2016).

In almost 40% of cases, DCM is genetically determined and associated with mutations in genes coding for titin (19–25%), lamin (5–6%), and sarcomeric thin (1–3%) or thick (3–4%) filament proteins. A variety of pathways and cellular structures are affected by these mutations with negative effects on mechanisms like calcium homeostasis, generation–transmission of mechanistic force in the myocardium, muscle contraction and ion channel function. The prevailing pattern of inheritance is autosomal dominant, with incomplete, penetrance, and variable age-related expression. The complex interaction between common and rare variants, the presence of additional modifier gene mutations or polymorphisms, as well as a number of environmental factors, may be responsible for the clinical heterogeneity of DCM even in families carrying the same pathogenic gene variant (Bonde et al., 2018). While the etiology of a wide proportion of cases remains unknown after genetic testing (the so-called “idiopathic” DCM), these apparently “non-genetic” forms, even when clearly acquired (e.g., alcohol- or chemotherapy-related or post-partum cardiomyopathies), are often influenced by the individual genetic profile (McNally and Mestroni, 2017). On the other hand, the pathogenicity of a gene mutation is modulated by interfering factors like age, the hormonal milieu, the status if the innate immune system, the presence of comorbidities such as chronic inflammatory diseases or hypertension, inherited mitochondrial alterations or the exposure to specific environmental triggers (such as cardio-toxic substances or drugs); all these can profoundly alter the clinical phenotype as well as the outcome. In this complex scenario, understanding genotype–phenotype correlations represents the

Frontiers in Physiology | www.frontiersin.org 2 May 2020 | Volume 11 | Article 368
TABLE 1 | Principal pathogenic gene mutations described in genetic DCM along with their clinical and cellular phenotype.

| Gene                      | Prevalence                                                                 | Clinical phenotype                                                                 | # hiPSC studies (References)                                                                 | Functional output                  |
|---------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|------------------------------------|
| Titin (TTN)               | 19–25% of familial forms 11–18% of sporadic forms                         | Usually milder forms of DCM, with LV reverse remodeling described after OMT. Can be associated with tibial muscle dystrophy and HCM (McNally and Mestroni, 2017). Truncating variants are related to alterations in mitochondrial function, increased interstitial fibrosis and reduced hypertrophy, along with increased ventricular arrhythmias at long-term follow-up, with a similar survival and overall cardiac function with respect to idiopathic DCM (Verdonschot et al., 2018). | 5 (Hinson et al., 2015; Streckfuss-Bomeke et al., 2017; Chopra et al., 2018; Schick et al., 2018; Zaunbrecher et al., 2019) | Contractile deficit               |
| Lamin A/C (LMNA)          | 5–6% of genetic DCM                                                       | Malignant DCM characterized by young onset, high penetrance, dysrhythmias (sinus node dysfunction, AF, atrioventricular node dysfunction, VT, VF, SCD), LV dysfunction and HF with reduced survival and frequent need for HT. Cardiac conduction system disease usually precedes the development of LV dilation and dysfunction (Hasselberg et al., 2018). | 6 (Su et al., 2012; Wyles et al., 2016a; Lee et al., 2017; Bertero et al., 2019; Salvarani et al., 2019; Shah et al., 2019) | LMNA haploinsufficiency; conduction defects; contractile defects |
| β-Myosin heavy chain (MYH7)| 3–4% of DCM                                                               | Sarcomeric rare variant carriers show a more rapid progression toward death or HT compared to non-carriers, particularly after 50 years of age (Merlo et al., 2013). | ?                                                                                           |                                    |
| Cardiac troponin T (TNN2) | 3% of DCM                                                                 | Clinical and prognostic profiles depend on type of mutation: carriers of Arg92Gln mutation have a worse prognosis than those with other mutations in TNN2 or other sarcomeric genes (Ripoll-Vera et al., 2016). | 6 (Sun et al., 2012; Wu et al., 2015; Broughton et al., 2016; Burridge et al., 2016; Wang L. et al., 2018; Shafaattalab et al., 2019) | Calcium handling abnormalities; contractile defects |
| Type V voltage-gated cardiac Na channel (SCN5A) | 2–3% of DCM                                                             | Arrhythmias (commonly AF) and myocyte dysfunction leading to progressive deterioration of LV systolic function (Bondue et al., 2018). Overlapping phenotypes: LQT, Brugada. | 1 (Moreau et al., 2018) | Electrophysiological defects; Arrhythmias |
| RNA-binding protein 20 (RBM20) | 1–5% of DCM                                                              | Malignant arrhythmic phenotype with high frequency of AF and progressive HF (Ripoll-Vera et al., 2016). | 3 (Wyles et al., 2016a,b; Streckfuss-Bomeke et al., 2017) | Calcium handling abnormalities; contractile defects |
| Desmoplakin (DSP)         | 2% of DCM                                                                 | Associated with Carvajal syndrome (autosomal recessive genetic disorder characterized by woolly hair, striate palmoplantar keratoderma and DCM). Additional phenotypic signs: dental abnormalities and leukonychia. LV dilatation usually asymptomatic at an early age. DCM progresses rapidly, leading to HF or SCD in adolescence (Yermakovitch et al., 2018). | 1 (Ng et al., 2019) | ACM |
| Dystrophin (DMD, Xp21.1 locus 16) | <2% of genetic DCM                                                      | Associated with Duchenne and Becker muscular dystrophy. Severe cardiac involvement in Duchenne (milder and later onset in Becker muscular dystrophy) with supraventricular arrhythmias, atrio-ventricular blocks and right bundle branch block, progressive LV dysfunction and HF (Mestroni et al., 2014). | 20 (Dick et al., 2013; Guan et al., 2014; Zatti et al., 2014; Lin et al., 2015; Macadiangdong et al., 2015; Japp et al., 2016; Nanni et al., 2016; Young et al., 2016; Kyrychenko et al., 2017; Zhang et al., 2017; Long et al., 2018; Caluori et al., 2019; Eisen et al., 2019; Farini et al., 2019; Jelinkova et al., 2019; Min et al., 2019; Pioner et al., 2019a; Sato et al., 2019; Tsurumi et al., 2019; Moretti et al., 2020) | Calcium handling abnormalities; contractile defects |
| α-Tropomyosin (TPM1)      | 1–2% of DCM                                                               | Overlapping phenotypes: LVNC, HCM (McNally and Mestroni, 2017) | 1 (Takasaki et al., 2018) | Sarcomere defects |

(Continued)
| Gene                        | Prevalence                        | Clinical phenotype                                                                 | #hiPSC studies (References) | Functional output               |
|-----------------------------|-----------------------------------|-------------------------------------------------------------------------------------|----------------------------|---------------------------------|
| Desmin (DES)                | 1–2% of DCM (Taylor et al., 2007) | Malignant phenotype associated with desminopathies and myofibrillar myopathy. Can cause a spectrum of phenotypes from skeletal myopathy, mixed skeletal–cardiac disease ("desmin-related myopathy"), and cardiomyopathy (DCM as well as HCM or RCM). DCM is typically preceded by skeletal myopathy and can be associated with conduction defects (Mestroni et al., 2014). | 1 (Tse et al., 2013) DES protein aggregates |
| Filamin C (FLNC)            | 1% of DCM                         | Cardiomyopathy associated with myofibrillar myopathy and LVNC; high rate of ventricular arrhythmias and SCD (particularly in truncating variants) (Ader et al., 2019). | ?                          |
| Metavinculin (VCL)          | 1% of DCM                         | Can cause either DCM or HCM phenotype (Vasile et al., 2006)                         | ?                          |
| Phospholamban (PLN)         | Rare (except for Netherlands where prevalence reaches 15% of DCM due to R14del mutation with founder effect) (van der Zwaag et al., 2012) | Early onset DCM with lethal ventricular arrhythmias. Low QRS complex potentials and decreased R wave amplitude, negative T waves in left precordial leads (Hof et al., 2019). PLN R14del mutation associated with high risk for malignant arrhythmias and end-stage HF from late adolescence, can cause either a DCM phenotype or ARVC (Mestroni et al., 2014). A milder phenotype is also reported (DeWitt et al., 2006). Electrophysiological defects | 4 (Karakikes et al., 2015; Stillitano et al., 2016; Ceholski et al., 2018; Stroik et al., 2019) |
| α-δ-/α-δ- Sarcoglycan (SGCA, SGCB, SGCD) | Rare                              | Recessive mutations in α-sarcoglycan linked to limb girdle muscular dystrophy 2F, dominant mutations in δ-sarcoglycan linked to DCM (Campbell et al., 2016). Ca handling abnormalities; Contractile defects | ?                          |
| α-cardiac actin (ACTC1)     | Rare                              | Familial atrial septal defect combined with a late-onset DCM (Frank et al., 2019). Can be associated with HCM and LVNC | ?                          |
| Cardiac troponin I (TNNA1)  | Rare                              | Overlapping phenotype: HCM (McNally and Mestroni, 2017). Telomere shortening        | 1 (Chang et al., 2018)     |
| Cardiac troponin C (TNNC1)  | Rare                              | Overlapping phenotypes: LVNC, HCM (McNally and Mestroni, 2017).                  | ?                          |
| Troponin I-interacting kinase (TNNA3K) | Rare                               | Conduction defect, AF (McNally and Mestroni, 2017).                               | ?                          |
| α-actinin 2 (ACTN2)         | Rare                              | Overlapping phenotype: LVNC (McNally and Mestroni, 2017).                         | ?                          |
| BCL2-associated anathogene 3 (BAG3) | Rare                               | Associated with myofibrillar myopathy (McNally and Mestroni, 2017).              | 1 (Judge et al., 2017) Disrupted myofibril; Contractile deficit |
| α-B-crystallin (CRYAB)      | Rare                              | Associated with protein aggregation myopathy (McNally and Mestroni, 2017).        | 1 (Mitzeifelt et al., 2016) Protein Aggregates; cellular stress |
| Titin-cap/telethonin (TCAP) | Rare                              | Associated with limb-girdle muscular dystrophy (McNally and Mestroni, 2017).     | ?                          |
| Muscle LIM protein (CSRP3)  | Rare                              | Overlapping phenotype: HCM (McNally and Mestroni, 2017).                         | 1 (Li et al., 2019) Calcium handling abnormalities |
| Cardiac ankyrin repeat protein (ANKRD1) | Rare                               | Associated with congenital heart disease (McNally and Mestroni, 2017).            | ?                          |
| Cipher/ZASP (LDB3)          | Rare                              | Overlapping phenotype: LVNC (McNally and Mestroni, 2017).                         | ?                          |
| Nebulette (NEBL)            | Rare                              | Overlapping phenotypes: LVNC, HCM (McNally and Mestroni, 2017).                  | ?                          |
| Emerin (EMD)                | Rare                              | Associated with Emery–Dreifuss muscular dystrophy (McNally and Mestroni, 2017).  | 1 (Shimojima et al., 2017) Calcium handling abnormalities |
TABLE 1 | Continued

| Gene | Prevalence | Clinical phenotype | #hiPSC studies (References) | Functional output |
|------|------------|--------------------|-----------------------------|-------------------|
| Sulfonylurea receptor 2A, component of ATP-sensitive potassium channel (ABCC9) | Rare | Associated with AF, Osteochondrodysplasia (McNally and Mestroni, 2017). | ? | |
| Potassium channel (KCNQ1) | Rare | Associated with AF, LQT1, short QT1, Jervell and Lange-Nielsen syndrome (McNally and Mestroni, 2017). | ? | |
| HSP40 homolog, C19 (DNAJC19) | Rare | Associated with 5-methylglutaconic aciduria, type V (McNally and Mestroni, 2017). | 1 (Rohani et al., 2020) | Mitochondrial abnormalities |
| Tafazzin (TAFD/4.5) | Rare | Associated with LVNC, Barth syndrome, endocardial fibroelastosis 2 (McNally and Mestroni, 2017). | 1 (Wang et al., 2014) | Mitochondrial defects; contractile defects |

ultimate challenge for translational research in the field of cardiomyopathies. Mutations in the TTN gene coding for titin, a giant protein that works as a nano-spring, account for most known genetic forms of DCM (19–25% of familial forms and 11–18% of sporadic forms), with incomplete penetrance and variable expression, frequently (but not always) presenting with relatively mild phenotypes and slow progression (Bondue et al., 2018). Conversely, mutations in the LMNA gene (lamin A/C, representing 5–6% of genetic DCM) (Hasselberg et al., 2018), FLNC (filamin C) (Ortiz-Genga et al., 2016), DES (desmin) (Capetanaki et al., 2015), PLN (phospholamban) (Schmitt et al., 2003), SCN5A (McNair et al., 2011), and mutations of RBM20, the regulator of TTN splicing (Refaat et al., 2012), have been identified as malignant causes of DCM, featuring a marked arrhythmic propensity in patients. The electrical instability characterizing these forms gives rise to a clinical overlap between DCM, arrhythogenic cardiomyopathy and channelopathies (Table 1), as these different disease may share a similar cellular and molecular basis of arrhythmogenesis, ultimately leading to an increased risk of sudden cardiac death (Gigli et al., 2019). Currently, lamin A/C gene mutations represent the only instance where the presence of a specific genetic background per se modifies clinical management, warranting consideration for the implantation of cardioverter defibrillators (ICDs), regardless of the severity of LV dysfunction (Priori et al., 2015).

CLINICAL PROFILE OF DYSTROPHIN-ASSOCIATED DCM

DMD is a severe disorder diagnosed in childhood: without supportive care, young men with DMD typically die in their late teens or early 20 s. Historically, the most common cause of death has been respiratory failure. However, with improved respiratory support and the introduction of steroid therapy, DMD cardiomyopathy is becoming an increasingly important cause of morbidity and mortality, due to HF and ventricular arrhythmias leading to sudden death (Eagle et al., 2002; McNally, 2007). From the clinical perspective, dystrophin-associated cardiomyopathy is characterized by a consistently severe phenotype (Table 1), and progresses relentlessly. Regional progression of contractile impairment (from the inferolateral wall to the rest of the LV) and diffuse/transmural replacement fibrosis of the inferolateral LV wall are common features of this form of DCM, relatively specific instrumental markers that help distinguish DMD-cardiomyopathy from other forms of DCM (Frankel and Rosser, 1976). LV dimensions and myocardial stiffness increase progressively as the extension of myocardial fibrosis (MF) increases (Figure 1). This, in turn, leads to an increased cardiac workload and to the activation of the renin angiotensin and the sympathetic nervous systems, thus leading to worse cardiac function and more severe HF-related symptoms and signs (Perloff, 1984). DMD patients are usually extremely limited in their mobility since the first decade, so that HF-related symptoms are often blunted by the relative lack of physical activity: overt cardiac symptoms have been reported in less than 30% of patients aged <18 (Nigro et al., 1990), underestimating the true extent and prevalence of HF in DMD subjects. Patients may complain about palpitations, dizziness or fainting, the latter commonly associated with the presence of conduction abnormalities at ECG (Fayssoil et al., 2017). Dyspnea is controlled by the mechanical ventilation used for neuromuscular respiratory failure: in this setting, peripheral edema and ascites are common findings and are related to the ventilator-driven positive intrathoracic pressures that reduce venous return (Nigro et al., 1990). Pleural effusion is frequently seen in end-stage disease (Fayssoil et al., 2014). Once HF appears the prognosis is poor, despite the extensive use of the complete therapeutic armamentarium including neuro-hormonal blockade. This is in contrast with other genetic forms of DCM where therapy can alter the progression of LV dysfunction and reverse remodeling is common (Japp et al., 2016; Ader et al., 2019). So far, no clear association between specific dystrophin genotypes and the severity of the cardiac phenotype has been established.

ECG abnormalities are often seen in DMD patients: the most frequently reported changes are sinus tachycardia, short PR intervals, deep and narrow “pseudo-necrosis” Q waves in
Management of DMD cardiomyopathy is challenging, due to the interplay of respiratory and cardiac manifestations, poor response to standard treatment and severe systemic manifestations of DMD. Moreover, large-scale randomized clinical trials (RCTs) are rare in this field. Therefore, the latest guidelines for the management of DMD cardiomyopathy are mostly based on the consensus of experts from a wide range of disciplines (Rakar et al., 1997; McNally et al., 2015).

Specifically, in the absence of dystrophin-specific targeted cardiac therapies, the 2014 NHLBI working group recommended the introduction of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) in boys with DMD by 10 years of age, in addition to traditional HF treatments (i.e., beta-blockers, mineralocorticoid receptor antagonists, diuretics), as LV dysfunction progresses (Silva et al., 2017). Steroid therapy primarily used to prolong ambulation, also showed a cardioprotective effect in DMD patients (Markham et al., 2008). Early initiation of noninvasive nocturnal ventilation increases long-term survival (McNally and Mestroni, 2017). The surveillance and management of arrhythmias in DMD patients is currently based on general adult HF recommendations. However, aggressive options such as an implantable cardioverter defibrillator (ICD) or the use of cardiac resynchronization therapy (CRT) is controversial in these patients, due to the limited life expectancy and the increased procedural risk (Wang M. et al., 2018). The same considerations apply to mechanical circulatory support (Iodice et al., 2015) and left ventricular assist devices (LVAD), rarely appropriate in this setting. Cardiac transplant is generally contraindicated in DMD (Rakar et al., 1997).

**DYSTROPHIN AND DYSTROPHIN-GLYCOGEN COMPLEX**

Dystrophin (DMD gene), the largest known gene in the human genome (2.5 million base pairs) (Mandel, 1989), was also the first found to be associated with DCM (Towbin et al., 1993). Ninety-nine percent of the mRNA transcribed from DMD gene is made by introns (non-coding sequences) and the coding sequence accounts for 86 exons. The full-length mRNA (14,000 bp) has a low tissue specificity and is detectable almost ubiquitously. Conversely, protein expression is confined to striated muscle and the neuromuscular junctions of the nervous system composed of mostly unmyelinated axons, dendrites and glial cell processes that forms a synaptically dense region containing a relatively low number of cell bodies. The obvious discrepancy between mRNA and protein distribution remains unresolved (Vogel and Marcotte, 2012). High levels of full-length dystrophin protein are present in both cardiac and skeletal myocytes, while the protein has a lower expression in unmyelinated axons, dendrites and glial cell processes forming synapsis-dense regions of the brain (“neuropil”). Notably, the DMD gene produces many protein isoforms for different tissue-specific functions (Muntoni, 2003). Specifically, introns are mostly based on the consensus of experts from a wide range of disciplines (Muntoni et al., 2003), owing to alternative splicing events. Splice variants are formed by exon skipping, i.e., exclusion of exons from primary transcripts, or by exon scrambling, i.e., subversion of the reciprocal order of exons in the transcript (Muntoni, 2003).

---

**FIGURE 1** | Cardiac magnetic resonance (CMR) cine imaging of a 24 years old DMD patient. The collection of representative images from patients was approved by the Ethical Committee of the Meyer Pediatric Hospital of Florence in the context of a project funded by Telethon Italy (grant GGP16191). Informed consent to patients was performed confirm the declaration of Helsinki. This data does not contribute to any novel finding. (A) Late gadolinium-enhancement (B) left ventricular (LV) short-axis section images of a patient with Duchenne muscular dystrophy (DMD). Yellow arrows indicate the inferolateral subepicardial and midwall contiguous fibrosis; light blue arrows indicate the anterior segment and the red arrows the posterolateral right ventricle wall, both showing midwall fibrosis; CMR cine imaging (C) and late gadolinium-enhancement (D) LV long-axis section images of the same patient with DMD; yellow arrows indicate midwall fibrosis of the inferolateral segment.
Full-length dystrophin (depicted in Figure 2, in the context of other DCM-related proteins) is a large rod-shaped protein with a molecular weight of 427 kDa, composed by 4 structural domains. The amino (N)-terminal domain has homology with α-actinin and binds, among other proteins, F-actin. The central rod-domain contains 24–25 spectrin-like repeats. The third one is a cysteine-rich domain. The last carboxy (C)-terminal domain associates at the C-terminal with β-dystroglycan and several other proteins to form a major protein complex referred to as the dystrophin glycoproteic complex (DGC) (Hoffman et al., 1987; Ervasti and Campbell, 1993). The DGC consists of α- and β-dystroglycan subunits, α-, β-, δ-, γ-, and ε-sarcoglycans, sarcospan, α- and β-syntrophins, α-dystrobrevin, and neuronal nitric oxide synthase (nNOS) (Mosqueira et al., 2013). DGC related-pathways include Ca\(^{2+}\) homeostasis and E-C coupling, mitochondrial function, motor protein interaction (sarcomere/Z-band), and gene expression. For instance, the acetylcholine receptor, the skeletal and cardiac isoforms of the voltage-gated sodium channels (Nav1.4 and Nav1.5, respectively), the L-type Ca\(^{2+}\) channel, aquaporin, and stretch-activated channel or transient receptor potential (TRP) cation channels (Shirokova and Niggli, 2013) are closely associated with the DGC via syntrophins. In the cardiac tissue, dystrophin is also associated to: Cavin-1 and Caveolin-3 (responsible for caveolae/T tubule formation), Ahnak1 (modulates L-type Ca\(^{2+}\) channel), CryAB (involved in cytoprotection and antiapoptosis), and Cipher (plays a role in muscle contraction maintaining the Z-line integrity and signaling). Dystrophin can be also target of phosphorylation by Calmodulin-dependent kinase II (CaMKII) that modulates the affinity for F-actin and syntrophin (Madhavan and Jarrett, 1994). Other short isoforms of dystrophin come from spliced variants and are expressed in several other tissues. In particular, the Dp71 is expressed in cardiac muscle and likely present in T-tubular membranes (Kaprielian and Severs, 2000; Kaprielian et al., 2000).
sodium channels (Nav1.4 and Nav1.5, respectively), the L-type Ca^{2+} channel, aquaporin, stretch-activated channels and other transient receptor potential (TRP) cation channels (Shirokova and Niggli, 2013) are closely associated with the DGC via syntrophins and are likely modulated by changes of dystrophin conformation. Moreover, in the myocardium dystrophin appears to serve as a signaling scaffold and membrane protein organizer, targeted by numerous signaling molecules that participate in a diverse set of pathways. For instance, it is also associated with Cavin-1 and Caveolin-3 (responsible for caveolae/T tubule formation), Ahnak1 (modulator of L-type Ca^{2+} channel), CryAB (involved in cytoprotection and antiapoptosis), and Cipher (involved in maintaining Z-line integrity and signaling). Dystrophin can be a target of phosphorylation by Calmodulin-dependent kinase II (CaMKII), modulating the affinity for F-actin and syntrophin (Madhavan and Jarrett, 1994). Other short isoforms of dystrophin originate from spliced variants and are expressed elsewhere. Specifically, Dp71 is expressed in cardiac muscle and is likely present in the T-tubular membrane (Kaprielian and Severs, 2000; Kaprielian et al., 2000). Another important protein is utrophin, a large (376 kDa) cytoskeletal protein, autosomal paralog of dystrophin with similar binding partners and structure that have been used to replace dystrophin in striated muscle, as a therapeutic strategy for DMD (Blake et al., 2002).

Mutations in DMD that shift the reading frame generate a truncated protein, which cannot anchor itself to the glycoprotein complex. The protein is, therefore, unstable and present at undetectable levels in muscle tissue. It is widely accepted that the predominant functional consequence of the lack of dystrophin is cellular vulnerability to mechanical stress associated with muscle contraction. Membrane fragility and altered Ca^{2+} homeostasis stem from the loss of dystrophin in both skeletal muscle fibers and cardiomyocytes, as demonstrated by studies in DMD animal models. These studies are consistent in showing that the absence of dystrophin leads to altered myogenesis and myofiber commitment in skeletal muscle, originally observed in X Chromosome-Linked Muscular Dystrophy (mdx, genetic mouse model of DMD that completely lacks full-length dystrophin) mouse embryos (Merrick et al., 2009) and skeletal muscle biopsies from human fetuses affected by DMD (Farini et al., 2016). Myogenesis was severely disrupted in mdx embryos, which displayed developmental delays including altered myotube size and shape, lower number of myotubes, displacement defects and aberrant Pax7-positive skeletal muscle stem cell behavior (Merrick et al., 2009). Moreover, Dumont and collaborators demonstrated that dystrophin is highly expressed in satellite cells (skeletal muscle stem cells) and regulates their polarity and asymmetric division. Hence, loss of dystrophin results not only in myofiber fragility but also – due to strikingly reduced asymmetric divisions – in the lack of regenerating myofibers (Dumont et al., 2015). Farini and collaborators proposed that PLC/IP3/IP3R/RyR1/Ca^{2+} signaling pathway may be activated differently in fetal compared to adult DMD skeletal muscle fibers, and proposed that this mechanism was directly linked to defects in myofiber formation and to a rearrangement in the expression of fast/slow-muscle specific genes (Farini et al., 2016).

A Developmental Role for Dystrophin in the Heart

The role of dystrophin during human cardiac development is still not completely deciphered. The absence of a shock absorber that may preserve membrane homeostasis and may be involved in several intracellular pathways is supposed to negatively affect physiological human myocardium formation. Previous studies reported that dystrophin is already expressed on the surface of cardiomyocytes in 8-week-old fetuses (Chevron et al., 1994) and, while no studies have investigated earlier phases of gestation, some authors hypothesize that specific fetal dystrophin isoforms may be present during early embryo development (Mora et al., 1994). Of note, a greater quantity of dystrophin was found in cardiac than skeletal muscle in fetuses, likely related to the earlier development of the myocardium. In the same study, Mora and colleagues reported that DGC proteins were expressed variably in period between 8 and 12 weeks of gestation. The expression of spectrin, a DGC-protein involved in the maintenance of plasma membrane integrity and cytoskeletal structure, was detected earlier than vinculin and talin (cytoskeletal proteins connecting integrins), suggesting that dystrophin is probably required on the sarcolemma before these two proteins. At 8 weeks, β-dystroglycan were found patchily on cardiac cells and immunostaining intensity did not appear to change with heart maturation. Adhalin (α-Sarcoglycan) did not appear in the cardiac tissue at 8 weeks and showed limited expression at 12 and at 16 weeks. The dystrophin-like protein utrophin was found at 8 weeks and faintly increased from 8 to 16 weeks (Mora et al., 1996). Finally, other authors identified a distinct pool of dystrophin molecules associated with myofibrils and localized within the Z-disks of the sarcomeres in association with α-actinin and desmin, in cardiac but not in skeletal muscle (Meng et al., 1996). Whether contractile function and dystrophin distribution influence each other in the early stages of development is still unknown.

HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED CARDIOMYOCYTES AS A MODEL OF DYSTROPHIN-ASSOCIATED CARDIOMYOPATHY

The advent of human induced pluripotent stem cells (hiPSCs) has opened the door to the exploration of core biomedical questions using personalized, renewable patient-specific human cell models instead of animal models. Cardiomyocytes derived from hiPSCs represent a unique platform to penetrate the pathophysiological processes related to early-stage defects underlying the onset and progression of DMD cardiomyopathy and delineate the so-called “cellular” phenotypes. Recent validation of these cellular
models compared to native myocardial tissue (Ronaldson-Bouchard et al., 2018), and the possibility to increase the level of maturation of hiPSCs using long-term cultures combined with nanostructured surfaces that mimic the extracellular matrix (Pioner et al., 2019a), will allow future research to comprehensively perform complex biophysical studies to simultaneously monitor membrane fragility, intracellular calcium handling and myofilament function. This represents a unique opportunity in the context of DCM, a disease rarely requiring surgical strategies and therefore difficult to study in vitro on human myocardial samples.

Notably, studies using patient-derived tissues often represent the final stages of disease, therefore separating primary mechanisms (i.e., those induced by the lack of full-length dystrophin) from the secondary mechanisms (i.e., those induced by chronic neurohormonal stimulation, adverse remodeling and effects of medications) is nearly impossible. On the other hand, small rodent models recapitulate facets of the human cardiomyopathy phenotype at the early stages of disease development. However, rat and mice cardiomyocytes differ from human cells in the expression of key contractile proteins, heart rate, electrical properties and ion channel function, often making it difficult to translate findings to humans. Cardiomyocytes obtained from the differentiation of iPSCs are the most prominent model to date for modeling human heart in vitro. Since the first report of Yamanaka and Takahashi in 2006, the reprogramming of somatic cells into embryonic-like induced pluripotent stem cells (iPSC) has becoming a widely used strategy for disease-in-a-dish modeling (Takahashi and Yamanaka, 2006). Generation of iPSCs bypass ethical concerns regarding disruption of embryos and, differently from embryonic stem cells (ESCs), can be derived directly from patients or healthy donors. Patient-derived iPSCs (hiPSCs) today provide the opportunity to characterize specific disease phenotypes in different tissues, thanks to tissue-specific differentiation protocols. Furthermore, targeting specific genes by CRISPR-Cas9 gene editing technology is a major resource allowing phenotyping of any cardiomyopathy-associated mutation, as well as a direct testing of the pathogenicity of variants of uncertain significance (Figure 3A).

It must be emphasized that, even after differentiation into cardiomyocytes, hiPSC-CMs retain immature features resembling developmental cardiomyocytes. In the very early phases (day 20–30 post differentiation), hiPSC-CMs exhibit fetal-type proteomic patterns (van den Berg et al., 2015), automaticity (spontaneous contraction), fetal-like ion channel expression (Davis et al., 2011), contractile properties (Pioner et al., 2016), and metabolism (Ulmer and Eschenhagen, 2019). A developmental-like behavior underlies the changes in hiPSC-CM structure and function. Using conventional culture conditions, cell growth, the organization of subcellular structures and the improvement of cardiomyocyte function are all time-dependent events. For instance, increase of repolarizing ion currents (I_{K1} in particular) and reduction of the funny current (I_{f}) decrease automaticity, together with a prolongation of cardiomyocyte action potential (Sartiani et al., 2007). Furthermore, sarcoplasmic reticulum calcium content becomes more prominent in the regulation of calcium handling (Itzhaki et al., 2006). Limited information is still available for the contractile apparatus. Sarcomere protein composition and isoform expression can be extremely variable in hiPSC-CMs. In a time window of 100 days after differentiation, hiPSC-CMs undergo sarcomere formation and isoform switch. This is similar to the process of fetal cardiac development (Sasse et al., 1993; Reiser et al., 2001; Racca et al., 2016), which occurs in vitro in a time-dependent manner. Furthermore, our current knowledge of sarcomere protein isoforms in hiPSC-CMs is limited by the lack of any truly effective chamber-specific differentiation protocol: for this reason, observations refer to the general cardiomyocyte population. At thick filament level, the cardiac fast alpha myosin heavy chain isoform (α-MHC, MYH6) and the atrial myosin regulatory light chain (MLC-2a, MYL7) are overall prevalent in hiPSC-CMs but long-term culture and stiff substrates (Weber et al., 2016) drive the isoform switch toward a predominant expression of the slow beta myosin heavy chain isoform (β-MHC, MYH7) and of the ventricular regulatory light chain (MLC-2v, MYL2) (Cai et al., 2019), and increase myosin binding protein C (cMyBP-C) expression (Cai et al., 2019). Titin (TTN) isoforms N2B and N2BA are co-expressed with a pattern similar to that found in the heart tissue of healthy individuals (Streckfuss-Bomeke et al., 2017). Sarcomeric protein composition is of extreme importance when modeling hiPSC-CM for the impact on contraction kinetics. In addition, some studies that used CRISPR-mediated genomic deletion in WT-hiPSC-CM lines for studying de novo sarcomere assembly reported that β-MHC, its connection with titin (Chopra et al., 2018) and the expression of the newly discovered Cronos titin (Zaunbrecher et al., 2019) are necessary for sarcomere assembly and function; non-muscle myosin II (NMM II) or α-MHC, instead, are not required. Another fundamental sarcomeric property is the Ca^{2+} buffering capacity of troponin C, which contributes to determine the Ca^{2+} sensitivity (pCa50) of myofibril tension development. Differences in thin filament protein isoform expression or phosphorylation patterns may account for changes in myofilament Ca^{2+} buffering. In hiPSC-CMs, prevalence of slow skeletal troponin I (ssTnI, TNNI1) may recapitulate properties typical of the embryonic age characterized by higher myofilament Ca^{2+} sensitivity and lower pH sensitivity, which may be particularly important for fetal hearts, which have modest amounts of Ca^{2+} delivered to the sarcomeres and are exposed to hypoxic conditions. As previously reported, the mechanisms responsible for the inhibition of myofilament force generation by acidosis include: (1) reduction in the affinity of troponin C (TnC) for Ca^{2+}, (2) alterations in thin filament activation, especially the TnI-TnC interaction, and (3) inhibition of the actin-myosin interaction (Wolska et al., 2001). Long-term culture (>90 days after differentiation) have shown co-expression (almost 1:1) of ssTnI with the adult cardiac troponin I isoform (cTnI) (Bedada et al., 2014; Pioner et al., 2016). Similarly, co-expression of slow skeletal Troponin T (ssTnT) and cardiac troponin T (cTnT) has been reported (Iorga et al., 2017). Of note, using the current differentiation protocols, we and other groups have found myofibril force comparable to fetal myofibrils and kinetic properties that more closely reflect those of adult ventricular
myofibrils expressing β MHC (Pioner et al., 2016; Racca et al., 2016; Iorga et al., 2017).

For this reason, maturation strategies applied to hiPSC-CMs are a primary challenge in the field. In the last few years, many researchers have explored ways to induce greater structure and function development of hiPSC-CMs, using a wide range of methods such as long-term culture (Lundy et al., 2013), biomimetic substrates (Macadangdang et al., 2014, 2015; Ribeiro et al., 2015), electrical or mechanical stimulation (Nunes et al., 2013), co-culture with other cell types (Tulloch et al., 2011), alteration of growth media (Birket et al., 2015) and 3D culture system such as engineered heart tissue (EHTs), heart on a chip or even in vivo neonatal rat heart system (Cho et al., 2017; Figure 3B). Since hiPSC-CMs possess features of developing cardiomyocytes, they can serve as human models for investigating the developmental time-course of early-stage cardiac diseases at cardiac cell level (Figure 3C).

**Modeling Early-Stages of DMD-Associated DCM Using hiPSC-CMs**

Cardiomyocytes derived from patient-hiPSCs can be considered a unique platform to address early-stage defects underlying DMD cardiomyopathy in a developing human heart. Models for inherited DCM have been obtained for mutated genes involving sarcomere and sarcomere Z-band stability, E-C coupling proteins, cytoskeleton, mitochondria and desmosomes (Table 1). Models for relatively common (arrhythmic right ventricular cardiomyopathies, laminopathies) as well as rare genetic syndromes associated with DCM (Friedreich’s ataxia, Barth syndrome, carnitine palmitoyltransferase II deficiency, LEOPARD syndrome, Pompe disease) have been reported (Burridge et al., 2016). Many studies using hiPSCs sought to mirror the pathomechanisms found in end-stage human samples or animal models, although none addressed in-depth the potential for novel therapeutic targets. Patient-derived hiPSC-cardiomyocytes and genome editing of DMD via CRISPR-Cas9 or TALEN can provide direct evidence that the lack of dystrophin directly impacts cardiomyocyte function. In normal hiPSC-CMs, full-length dystrophin (Dp427) is expressed early after differentiation. Recently, mass spectroscopy analysis has suggested that dystrophin is upregulated in a period of time from days 30 to 60 post differentiation. This is also supported by similar results in the developmental expression pattern of embryonic and postnatal mouse hearts (Cai et al., 2019). A lack of information limits the comprehension of the physiological role and expression levels of the Dp71 isoform and of utrophin. However, a novel transient dystrophin isoform (Dp412 kDa) was identified in hiPSCs during mesodermal differentiation induced by a 72 h exposure to bone morphogenetic protein 4 (BMP4), suggesting a role of shorter isoforms during development (Massourides et al., 2015). Furthermore, Jelinkova et al. (2019)
tested a WT hiPSC and two WT hESC lines and reported that Dp427 is already expressed before differentiation and that the absence of dystrophin leads to increased ROS production, NOS activity and DNA damage in DMD-hiPSCs (2 independent patients). These results further support the value of the hiPSC platform for modeling early-stages of DMD.

In such perspective, we have summarized the major findings and limitations of published DMD-hiPSC-CMs models in Table 2.

**Excitation Contraction Coupling of DMD-hiPSC Cardiomyocyte Models**

Calcium handling abnormalities have been described as a major consequence of dystrophin and other DCM-related mutations but the mechanistic progression remains unclear. A study from the Wu laboratory explored DCM-patient derived cell lines carrying the R173W-cTnIT mutation, reporting reduced sarcoplasmic reticulum calcium content and higher rate of spontaneous arrhythmic electrical activity compared to normal cardiomyocytes (Sun et al., 2012). In this mutant cell line, decreased cell contractility was determined by atomic force microscopy and compared with lines obtained from the non-affected members of the same family. Overexpression of the sarcoplasmic reticulum Ca$^{2+}$ adenosine triphosphatase (Serca2a) enhanced the intracellular Ca$^{2+}$ transient and restored force production (Sun et al., 2012). These and other works have provided reports of stem cell lines with DCM-associated mutations including RBM20 (Wyles et al., 2016a), PLB (Karakikes et al., 2015), EMD (Shimojima et al., 2017), or CSRP3 (Li et al., 2019), showing marked calcium handling abnormalities that may recapitulate the early myocardial alterations occurring in human DCM hearts. However, the underlying molecular mechanisms of myocardial dysfunction and damage in the presence of DCM-related mutations in various genes can be completely different despite the common final phenotype.

For DMD, two main hypotheses have been advanced: (1) membrane fragility or damage leading to membrane tear or rupture that facilitates abnormal calcium influx, as indirectly demonstrated by treating DMD cells with membrane sealants (i.e., Polaxamer 188) (Yasuda et al., 2005); (2) altered ion channel function and dysregulation of calcium homeostasis as a direct consequence of the altered dystrophin complex (Zhan et al., 2014). Guan and collaborators generated cardiomyocytes derived from the urine of a dystrophin-mutant DMD patient with a deletion of exon 50 (DMD-Δ exon 50), resulting in a dystrophin-deficient phenotype. DMD-Δexon50 displayed unique features such as increased membrane susceptibility to hypotonic stress, slower Ca$^{2+}$ transients in the early phases after differentiation and increased probability of mitochondrial permeability pore opening (Guan et al., 2014). Similarly, DMD cell lines with deletion of exons 49–50 (DMD-Δ exons 49–50) overexpressed the immunoproteasome subunits, while their inhibition by ONX-0914 (proteasome inhibitor) reduced the sarcolemmal damage, as indicated by decreased release of cTnI and TNF-α after treatment (Farini et al., 2019). Lin and collaborators described hiPSC-CM cell lines from two patients carrying out-of-frame deletion in DMD exons 45–52 (DMD-Δ exons 45–52). They reported DMD-CMs with profound reduction of the L-type calcium current and increased cytosolic Ca$^{2+}$ levels, and identified a downstream activation DIABLO-CASP3 that was related to mitochondrial apoptosis (Hinson et al., 2015). This mechanism is in keeping with the increased reactive oxygen species (ROS) levels found in DCM-CMs (Gartz et al., 2018; Jelinkova et al., 2019). The membrane sealant P188 (Polaxamer 188) was able to normalize the increased diastolic calcium levels and to revert the increase in the rate of apoptosis, supporting the hypothesis that membrane damage/fragility leads to intracellular calcium overload even in the early stages of myocardial differentiation (Lin et al., 2015). A unifying hypothesis may involve mechanosensitive channels, e.g., the transient receptor potential canonical channel 1 (TRPC1), which transduce membrane stretch into a cationic (Na$^+$, K$^+$, Ca$^{2+}$, and Mg$^{2+}$) flux across the sarcolemma, and may be gated by an excessive tension developed within the lipid bilayer, as previously reviewed (Maroto et al., 2005). In support of this idea, a recent test exposed DMD (DMD-Δ exons 43–45) and control hiPSC-CMs, plated on a fibronectin-coated silicon chamber, to a periodical mechanical stretching (120% elongation) at a frequency of 60 cycles per min and measured the response of intracellular calcium levels after 3 h (Tsurumi et al., 2019). A short-term mechanical stretch protocol was sufficient to increase diastolic calcium levels and calcium transient amplitude in DMD cells while it did not cause such effects in controls. However, these studies are limited by the small number of cell lines and by the use of immature cardiomyocytes in the early-phases of cardiac differentiation and maturation. We recently reported the analysis of calcium transients in hiPSC-CMs at day 100 of differentiation, comparing the DMD-Δ Exon 50 line to a healthy control and its CRISPR-Cas9 genome edited isogenic control (Exon 1 deletion in the DMD gene, DMD-c.263delG) (Pioner et al., 2019a; Figure 4). At this advanced stage of differentiation and maturation, hiPSC-CMs paced by field stimulation showed adaptation to frequency changes. DMD-Δ Exon 50 showed slower calcium transient rise and decay compared to controls, and these changes were comparable to those observed in our CRISPR-Cas9 generated cell line (DMD-c.263delG) expressing a shorter synthetic dystrophin. Slower duration of calcium transients is an alteration found in other DMD cell lines (Figure 4C). Both cell lines were associated with prolonged cardiomyocyte relaxation at low loading conditions (Figure 4D). This directly demonstrated that the lack of the full-length dystrophin is sufficient to perturb normal contractility of cardiomyocytes, with abnormal calcium homeostasis as a leading consequence. Moreover, another recent study generated a cell line from a male patient (DMD-c.5899C>T) and from a DMD female carrier (Δ Exons 8–12). Interestingly, both DMD cell lines showed prolonged action potential (AP) duration compared to control lines, and those measured in cells from the female carrier were even larger (APD90, 600 vs. 400 ms in the male patient). The prolongation of APs was attributed to an increase of L-type calcium ($I_{Ca-L}$) peak current amplitude and CACNA1C expression ($I_{Ca-L}$ main channel subunit), which were even more evident in the iPSC-CMs obtained from the female carrier. Regulation or expression of ion channels might be dependent
### TABLE 2 | DMD-cardiomyopathy studies based on hiPSC-CMs: individual mutations vs. functional parameter and therapeutic attempts in vitro.

| Mutation/parameter | Membrane | Electrophysiology | Calcium handling | Sarcomere | Metabolism and oxidative stress | Therapeutic approach | References |
|--------------------|----------|-------------------|------------------|-----------|-------------------------------|---------------------|------------|
| Δ Exon 50          | Fragility/damage | Slower calcium transients | ↓ myofibril force, slower myofibril relaxation, ↑ myofibril calcium sensitivity | ↑ mPTP opening; unaffected mitochondrial respiration | | | Guan et al., 2014; Macadangdang et al., 2015; Pioner et al., 2019a |
| Exons 49–50        | Fragility/damage | ↑Spontaneous electrical activity | ↑ Intracellular diastolic calcium level | ↑cTnI release (marker of cell damage) | ONX-0914 reduced ROS level | | Farini et al., 2019 |
| DMD: nonspecified mut. | | | | | Reduced Nup153 factor (regulates cardiac remodeling) | | Nanni et al., 2016 |
| Δ Exons 45–52      | Fragility/damage | ↑ Intracellular diastolic calcium level | ↓ Sarcomere transcriptome | Mitochondrial damage, CASP3 activation, apoptosis | Poloxamer 188, reduced resting cytosolic Ca²⁺ level, CASP3 activation and apoptosis | | Lin et al., 2015 |
| c.263ΔG            | Fragility/damage | Slower calcium transients | ↓ Alignment; ↓acto-myosin turnover; cellular hypertrophy | | | Macadangdang et al., 2015; Pioner et al., 2019a |
| Δ Exon 52–54       | | | | | NOS-induced ROS release | | Jelinkova et al., 2019 |
| Δ Exons 43–45      | | | ↑ Stretch-induced intracellular calcium entry | | | Tsurumi et al., 2019 |
| Δ Exons 8–12       | | ↑I<sub>Ca,L</sub> density; prolonged APD | | ↓ Force production | Rescue by CRISPR-Cas9-deletion of 3–9, 6–9, 7–11 | | Eisen et al., 2019 |
| c.5899C > T        | | ↑I<sub>Ca,L</sub> density; prolonged APD | | | | | Eisen et al., 2019 |
| Δ Exon 8–9         | ↑Spontaneous electrical activity | Slower calcium transients | | | | | Kyrychenko et al., 2017 |
| Δ Exon 3–6         | | | Mitochondrial damage; ↑ROS level ↑exosome protection | Exosome protection | | | Gartz et al., 2018 |

(Continued)
TABLE 2 | Continued

| Mutation/parameter | Membrane | Electrophysiology | Calcium handling | Sarcomere | Metabolism and oxidative stress | Therapeutic approach | References |
|--------------------|----------|-------------------|------------------|-----------|-------------------------------|----------------------|------------|
| Δ Exons 45–50      |          | ↑Spontaneous electrical activity |                  |           |                               | Caluori et al., 2019 |
| Δ Exons 48–50      |          |                   |                  |           |                               | Young et al., 2016 |
| Δ Exons 46–55      | Fragility/damage | Cellular arrhythmias |                  |           |                               | Sato et al., 2019 |
| Δ Exon 44          |          |                   |                  |           |                               | Min et al., 2019 |
| Exon 45, 51, 45, 53, 46, 52, 50, 43, 6, 7, 8, 55 | CRISPR-Cas9 restoration |                         |           |                               | Long et al., 2018 |
| Δ Exons 48–50      |          | ↓Force production  |                  |           |                               | Zhang et al., 2017 |
| Δ Exons 4–43       |          | ↓Force production  |                  |           |                               | Zatti et al., 2014 |
| Δ Exons 48–50, 47–50, Δ TG from exon 35, c.3217G > T | Antisense oligonucleotide-mediated skipping of exon 51 and delivery of dystrophin minigene |                           |           |                               | Dick et al., 2013 |
| Δ Exon 52          |          | Slower calcium transients; arrhythmic events |                          |           |                               | Moretti et al., 2020 |
on the specific protein defects rather than on the common downstream pathways related to cell degeneration toward a DCM phenotype. For instance, another DCM-hiPSC model was obtained from patients harboring a fukutin-related protein gene mutation (826C > A; Leu276Ile, transmembrane protein) associated to Limb-Girdle muscular dystrophy (LGMD) and was studied at comparable levels of maturation. In this case, the authors reported DCM-hiPSC-CMs with reduced spike amplitude and shorter AP duration compared to healthy controls, with reduced peak and late Na currents (I_{Na}), as well as lower peak L-type calcium channel current; these changes were likely related to the reduced expression of their related genes, SCN5A and CACNA1C. In addition, the rapidly activating delayed rectifier potassium current (I_{Kr}) was reduced, whereas the transient outward current (I_{to}) and slowly activating delayed-rectifier potassium current (I_{Ks}) were similar in DCM and control cardiomyocytes (El-Battrawy et al., 2018).

**Force and Contractile Properties of DMD-hiPSC Cardiomyocyte Models**

The N-terminal domain of dystrophin has homology for cytoskeletal F-actin and interacts in the context of costamere domains that couple sarcolemma to sarcomeric Z-bands. As cardiac cells rapidly shorten during contraction, electrostatic interaction between the basic spectrin repeats and actin filaments serve to dampen elastic extension during stretch (Ervasti, 2007). In this context, a complex network involves multiple DCM-related proteins including the sarcomere proteins titin (TTN), β-myosin heavy chain (β-MHC), cTnT, cTnl, cTnC, tropomyosin...
cardiac troponin I (cTnI)–interacting kinase (TNNI3K) and other Z-band interacting proteins such as α-actinin, desmin, telethonin, cardiac ankyrin repeat protein, nebulotta, α-B-crystallin and ciper. The Z-band complex seems to be involved in the mechanosensory mechanisms that convert mechanical stimuli into biochemical signals, and dystrophin has connections with several Z-band proteins. Consequently, DMD-with Δexon50 displayed less adaptiveness to variations of the topographical cues (cell and sarcomere alignment), which was related to reduced actin turnover, as studied by fluorescence recovery after photobleaching (FRAP). This behavior was reproduced in a DMD CRISPR-Cas9 gene-edited cell line (Macadangdang et al., 2015). By comparison, hiPSC-CMs with a mutation in the RBM20 gene exhibited heterogeneous sarcomeric organization patterns. RBM20-engineered heart tissues (EHTs) showed impaired force of contraction and increased passive tension that was associated to a lower degree of the switch from the N2BA to the N2B isoform of titin, as a consequence of the S635A RBM20 mutation impacting on RNA splicing and transcription (Streckfuss-Bomeke et al., 2017). In a different way, loss of dystrophin may impact both cytoskeletal F-actin and sarcomeric actin in cardiomyocytes. 

Myofibrils are the most abundant organelles of adult cardiomyocytes, occupying approximately 50–60% of the cytoplasmic volume. However, myofibrils are less represented in the contractile machinery of hiPSC-CMs, in which the sarcomere bands and lines gradually form in the advanced stages of maturation (Gherghiceanu et al., 2011). In this context, we investigated whether loss of dystrophin may affect the contractile properties at single myofibril level by applying a cell skinning protocol followed by tissue homogenization to obtain single myofibrils, which were studied using a custom-made force-recording apparatus with fast solution switching, as previously described (Pioner et al., 2016). We found reduced tension production upon Ca-mediated activation in DMD myofibrils, as compared to controls. However, the kinetics of force development ($k_{DF}$) and relaxation (slow $k_{REL}$) after calcium removal were not different, suggesting no changes in the rate of crossbridge cycling during tension development and detachment. Also, we found a slower fast phase of relaxation (fast $k_{REL}$), which is mainly regulated by inter-sarcomere dynamics (Pioner et al., 2019a; Figure 4D), paralleled by a slower contraction (shortening) of intact cells (Figure 4B). Altered myofibril contractile function could be related to developmental alterations, although the mechanism is not clear (Figure 4A). This should encourage future studies to better define the fundamental role of sarcomere protein composition for the definition of contractile properties. Another group investigated mutations in the dystrophin actin-binding domain (ABD1) causing truncated forms of dystrophin (DMD-Δ Exon 3–9, 6–9, or 7–11). Force measurements using multicellular preparations (engineered heart muscle, EHM) displayed lower force in DMD-mutant cell lines and the de novo insertion of the missing exon using CRISPR-Cas9 technology only partially restored the contractile performance. Among other DCM models, the hiPSC-CMs with absence/reduction of full-length dystrophin may be able to evaluate the functional consequences of dystrophin loss and elucidate the role of a variety of proteins interacting around the N-terminal of full-length dystrophin, which are still elusive.

OVERCOMING THE LIMITATIONS OF HIPSC-CMS: PATIENT-SPECIFIC VALIDATION AND HIGH-THROUGHPUT STUDIES

To date, the possibility of using hiPSC-CMs to predict individual prognosis or response to therapies is limited by lack of direct validations, that is, patient-specific hiPSC-CMs have never been tested against actual adult cardiomyocytes from the same patient or from patients with a similar condition. This is due to the poor availability of human samples from patients with cardiomyopathies or other arrhythmogenic conditions, and the limited experience of many research centers in investigating fresh human myocardium and cardiomyocytes (Tardiff et al., 2015). We have recently developed a technique (Coppini et al., 2014) to isolate single ventricular cardiomyocytes and trabecule from the surgical samples of obstructive HCM patients. We were therefore able to study adult CMs in order to characterize the functional abnormalities of action potentials, ion currents, Ca$^{2+}$ handling, myocardial contraction and relaxation, and test the effectiveness of different ion channel blockers such as ranolazine or disopyramide (Coppini et al., 2013; Coppini et al., 2018; Ferrantini et al., 2018). In Pioner et al. (2019b), we compared the physiological properties of iPSC-CMs from an healthy donor, differentiated using nanopatterned surfaces and long-term cultures, with those of adult cardiomyocytes from non-failing non-hypertrophic surgical patients (Pioner et al., 2019b). In terms of action potential shape and duration, calcium transient properties and response to β-adrenergic agonists, hiPSC-CMs at an advanced degree of maturation closely approximated the features of freshly isolated human adult cardiomyocytes (Pioner et al., 2019b). While obtaining fresh cardiac samples from DMD patients is hardly feasible, our technique can be developed to allow the isolation of cardiomyocytes from intramyocardial biopsies, to be used for functional studies in selected patients, allowing a direct comparison with individual hiPSC-CMs. Moreover, in order to improve hiPSC-CM maturation, single cardiomyocytes or 3D cultures (engineered heart tissues; Gupta et al., 2018) could be challenged during maturation using electrical stimulation at different pacing rates and periodic stretch-release protocols, simulating the contraction-relaxation cycle of the native heart (Sun and Nunes, 2017; Ronaldson-Bouchard et al., 2019). Such approach to cardiomyocyte differentiation might be easily achieved using smart contractile materials as culture substrates, such as liquid-crystal elastomer, which we recently developed and characterized (Martella et al., 2017; Ferrantini et al., 2019).

The possibility offered by hiPSC-CMs to identify patient- or mutation-specific mechanisms of disease and test novel therapies in a personalized manner is hampered by the fact that current approaches are extremely costly and time consuming. The development of rapid high-throughput assays to study the pathophysiological features of different hiPSC-CM lines and
test novel therapeutic approaches is therefore warranted. We recently developed a system to simultaneously record action potentials and intracellular Ca\(^{2+}\) from multiple iPSC-CMs using a fast camera, paralleled by a streamlined data analysis system to rapidly extract the main functional biomarkers from each recording (Pioner et al., 2019b). In an attempt to further improve the throughput of cell-line analysis, a possible approach would be an all-optical semi-automatic platform combining the parallel detection of multiple functional properties with electrode-free optogenetic control of electrical function in the sample. This approach would be feasible using genetically encoded voltage indicators (GEVIs) or calcium indicators (GECIs) (Kaestner et al., 2014; Huebsch et al., 2015; Shaheen et al., 2018) and gene-encoded actuators (channelrhodopsin) (Klimas et al., 2016). Such comprehensive platform, when combined with a semi-automated experimental-control and analysis system (Klimas et al., 2016), will allow repeatable longitudinal prolonged evaluations of iPSC-CMs at different time points and facilitate the evaluation of their response to different treatments. In addition to these technologies, CRISPR-Cas9 gene repair was recently improved by the newly discovered CRISPR-Cpf1 nuclease (Zhang et al., 2017). CRISPR-Cpf1 is driven by a single RNA guide (gRNA) and prefers T-rich protospacer adjacent motif (PAM) sequences: this feature is important for the potential correction of other disease-related mutations, because not all mutation sites contain G-rich PAM sequences for SpCas9 or PAMs for other Cas9 orthologs. Importantly, Cpf1 is about 140 ammunoacids smaller than the most widely used SpCas9, which can potentially enhance the packaging and delivery by adenovirus, adeno-associated (AAV) or other viral constructs. Finally, Cpf1 can be used to permanently correct DMD mutations, restoring dystrophin expression and efficiently preventing the progression of the disease, as reported in DMD patient-derived iPSCs and mdx mice. The combination of biophysical approaches with the breakthrough of increasingly precise genome editing techniques may pave the way to a truly personalized medicine for DMD patients.

### TABLE 3 | Gene therapy strategies and application to hiPSC-CM models to restore dystrophin function.

| Approach                     | Target mutation type          | Dystrophin product | Strengths                                      | Challenges                                      | hiPSC-CM                        |
|------------------------------|-------------------------------|--------------------|------------------------------------------------|------------------------------------------------|----------------------------------|
| Stop codon readthrough       | Nonsense point mutations      | Complete           | • Well-tolerated (PTC124 or ataluren)          | • Low efficiency in the heart                   | ?                                |
| AON-mediated exon skipping    | Frameshift mutations          | Lacking existing deletion and additional exon(s) | • Well-tolerated • Effective at cell level     | • Poor cardiac uptake of PMO                   | Efficacy ?                       |
| AAV micro-dystrophin         | not interacting with endogenous gene | Extensively truncated but functional | • High efficacy in heart • High efficacy in skeletal muscle • Lasting (multiple years) | • Potentially immunogenic • Potential for null effect with pre-existing immunity | ?                                |
| CRISPR-Cas9                  | Frameshift, insertion, and nonsense mutations | Depends on editing strategy [ranging from complete to lacking deletion and additional exon(s)] | • High efficacy in heart and skeletal muscle • Versatile • Genomic correction is life-long (theoretically) | • Potentially immunogenic • Risk of off-target editing • Low number of amenable mutations for each AON drug | Efficacy ?                       |

FROM BENCH TO BED SIDE

Four groups of molecules are currently in use in the clinical management of patients with DMD cardiomyopathy: renin-angiotensin-inhibiting agents, beta-adrenergic receptor blockers, mineralocorticoid receptor antagonists and corticosteroids. Although useful for symptom management, none of these molecules is capable of modifying the natural history of the disease. Currently, none of the stem cell-based studies have reported or suggested novel pharmacological approaches for dystrophin-associated cardiomyopathies. Few pilot tests on animal models were attempted, using a membrane sealant...
of dystrophin. As shown in Table 3, upon identifying the exact molecular consequences of the lack of functional dystrophin expression, their success is less dependent on whether or not dystrophin expression can be re-established in the heart by proteasome inhibitors (Lin et al., 2015) or an immunoproteasome inhibitor (Farini et al., 2019), but these agents are not currently under development for use in patients. In other DCM models, a limited number of disease modifying therapeutic approaches were attempted, including the overexpression of Serca2a by viral-vector gene-therapy (Sun et al., 2012), and the modulation of SERCA/PLN through the mechanoreceptor protein integrin-linked kinase (ILK) (Traister et al., 2014). Indeed, most of the DCM hiPSC studies sought to identify novel mechanistic targets and were only labeled as a promising platform for a pharmacological therapy, but never used for an actual pharmacological validation. This is undoubtedly related to the immaturity of hiPSC-CM models and the fact that findings obtained using in vitro models cannot be so easily translated into trials in vivo.

In recent years, potentially curative approaches for DMD have begun to take shape. Unlike small molecule treatments, CRISPR-Cas9 or TALEN gene-targeted therapies are designed with the goal to induce expression of a functional gene product that will reestablish normal myocyte physiology. Since these therapies aim to repair the original defect in the cell by restoring functional dystrophin expression, their success is less dependent on identifying the exact molecular consequences of the lack of dystrophin. As shown in Table 3, major efforts involved the use of CRISPR-Cas9 in the design of mutation-specific therapies, which include exon skipping, reframe or deletion of portions in the DMD gene. Notably, successful restoration of contractile function was observed in a large group of hiPSC models carrying mutations in the ABD domain (mostly linked to BMD) or in the central domains (mostly associated to DMD) (Kryuchenko et al., 2017; Zhang et al., 2017; Long et al., 2018; Min et al., 2019). For this purpose, more effort should be moved toward the generation of BMD-patient cell lines (Gowran et al., 2018), as this patient group frequently diagnosed mid-life and is definitely an understudied group. In addition, BMD patients appear to be the most promising candidates for autologous cell transplantation as well as for in vitro studies aimed at identifying specific, novel targets that emerge in the presence of semi-functional truncated dystrophin proteins. Current strategies still lack the ability to obtain a lasting and efficient correction of the primary defect. In addition, DMD and BMD are associated with a variety of different mutations in the DMD gene. Therefore, a host of different therapeutic approaches are required for different patient subgroups, depending on the site and nature of their mutation. For instance, PTC124 (Ataluren) has been used in Europe to treat DMD patients carrying nonsense mutations (10% of total variants; Bladen et al., 2015). PTC124 renders ribosomes less sensitive to premature stop codons by promoting insertion of near-cognate tRNA at the site of nonsense codons with no apparent effects on downstream transcription, mRNA processing, or stability of the resulting protein, thereby allowing the production of functional dystrophin proteins. Ataluren works particularly well for the stop codon “UGA” (Welch et al., 2007). For this reason, the drug could be eligible for preclinical personalized tests on patient-specific stem cell-based models, which have been rarely attempted so far (Koopmann et al., 2012; Lee et al., 2017). Finally, innovative therapeutic approaches may consider repositioning drugs in use for other conditions or strategies acting on molecular factors that induce or downregulate common molecular pathways involved in genetic cardiomyopathies. Although such “universal” approaches will not restore dystrophin expression in the heart, they could still delay disease progression, be well tolerated, and be appropriate for a broader range of patients with DMD.

CONCLUSION

In this review, we analyzed the current insights of DMD-associated cardiomyopathy, from the clinical aspects to innovative disease modeling based on human iPSC derived cardiomyocytes, in the attempt to decipher specific mechanisms underlying DCM pathogenesis in DMD patients. Human models of iPSC-cardiomyocytes are a viable cell-based platform for investigating the human cardiac phenotype resulting from specific gene mutations. These models can recapitulate the facets of the physiology and pathophysiology of native cardiomyocytes, opening new opportunities for research. hiPSC-cardiomyocytes allow the study of unique individual patients without reliance on isogenic strains of animals and avoiding invasive biopsies of human cardiac tissue samples. Their progressive maturation of their cardiac phenotype, obtained with advanced differentiation techniques, is a powerful tool for investigating the early-stage consequences of dystrophin mutations that DMD, and their effects on cardiac development. Existing studies suggest that the pathogenic mechanisms appear early in the disease progression as a combination of the developmental consequences of the absence of full-length dystrophin (Dp427) in cardiomyocytes. Gene therapy with micro dystrophin, up-regulation of utrophin or exon skipping approaches are currently the most promising ways to rescue or at least mitigate the DMD phenotype. For this reason, despite the obvious limitations related mostly to their immature phenotype, the advent of hiPSC-cardiomyocytes presents a unique opportunity to improve our approach to the understanding of the pathophysiology of DMD cardiomyopathy.

AUTHOR CONTRIBUTIONS

JP, AF, and CF contributed to the design and wrote the manuscript in consultation with RC, LS, MD, SF, CP, and IO. JP and NC performed the meta-analysis and prepared figures and tables. All authors critically reviewed the manuscript and declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

FUNDING

This work was supported by Fondazione Telethon Italy (GGP16191), Fondazione Telethon-UILDM (GUP19012), 777204/ Horizon 2020 (SILICO-FCM project).
REFERENCES

Ader, F., De Groote, P., Réant, P., Rooyck-Thombo, C., Dupin-Deguine, D., Rambaud, C., et al. (2019). FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations. Clin. Genet. 96, 317–328. doi: 10.1111/cge.13994

Bedada, F. R., Chan, S. S., Metzger, S. K., Zhang, L., Zhang, J., Garry, D. J., et al. (2014). Acquisition of a quantitative, stoichiometrically conserved ratiometric marker of maturation status in stem cell-derived cardiac myocytes. Stem Cell Rep. 3, 594–605. doi: 10.1016/j.stemcr.2014.07.012

Bertero A, FIELDS PA, Smith AT, Leonard A, Beussman K, Sniadecki NJ, et al. (2019). Chromatin compartment dynamics in a haploinsufficient model of cardiac laminopathy. J. Cell Biol. 218, 2919–2944. doi: 10.1083/jcb.20190211

Burridge, P. W., Diecke, S., Matsa, E., Sharma, A., Wu, H., and Wu, J. C. (2016). Modeling cardiovascular diseases with patient-specific human pluripotent stem cell-derived cardiomyocytes. Methods Mol. Biol. 1353, 119–130.

Cai W, Zhang J, de Lange WJ, Gregorich ZB, Karp H, Farrell ET, et al. (2019). An unbiased proteomics method to assess the maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 125, 936–953. doi: 10.1161/CIRCRESAHA.119.315305

Caluori, G., Pribyl, J., Pesl, M., Jelinkova, S., Rotrekl, V., Skladal, P., et al. (2019). An unbiased proteomics method to assess the maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 125, 936–953. doi: 10.1161/CIRCRESAHA.119.315305

Ervasti, J. M., and Campbell, K. P. (1993). A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 108ñ117.

Fayssoil, A., Abasse, S., and Silverston, K. (2017). Cardiac Involvement of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes. Stem Cells 3990

Eisen, B., Ben Jehuda, R., Cuttitta, A. J., Mekies, L. N., Shemer, Y., and Baskin, P. (2019). Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients. J. Cell. Mol. Med. 23, 2125–2135. doi: 10.1111/jcmm.14124

El-Battrawy, I., Zhao, Z., Lan, H., Li, X., Yucel, G., Lang, S., et al. (2018). Ion channel dysfunctions in dilated cardiomyopathy in limb-girdle muscular dystrophy. Circ. Genomic Precis. Med. 11:e001893. doi: 10.1161/CIRCGEN.117.001893

Ervasti, J. M. (2003). Costameres: the achilles heel of herculean muscle. Dev. Cell 115, 9276ñ9281.

Ervasti, J. M., and Campbell, K. P. (1993). A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 108ñ117.

Fayssoil, A., Abasse, S., and Silverston, K. (2017). Cardiac Involvement of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes. Stem Cells 3990

Eisen, B., Ben Jehuda, R., Cuttitta, A. J., Mekies, L. N., Shemer, Y., and Baskin, P. (2019). Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients. J. Cell. Mol. Med. 23, 2125–2135. doi: 10.1111/jcmm.14124

El-Battrawy, I., Zhao, Z., Lan, H., Li, X., Yucel, G., Lang, S., et al. (2018). Ion channel dysfunctions in dilated cardiomyopathy in limb-girdle muscular dystrophy. Circ. Genomic Precis. Med. 11:e001893. doi: 10.1161/CIRCGEN.117.001893

Ervasti, J. M. (2003). Costameres: the achilles heel of herculean muscle. J. Biol. Chem. 278, 13591ñ13594.

Ervasti, J. M. (2007). Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochem. Biophys. Acta 1772, 108–117.

Ervasti, J. M., and Campbell, K. P. (1993). A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. 122, 809–823.

Farini, A., Gowan, A., Bella, P., Sitizia, C., Scopece, A., Castiglioni, E., et al. (2019). Fibrosis rescue improves cardiac function in dystrophin-deficient mice and Duchenne patient-specific cardiomyocytes by immunoproteasome modulation. Am. J. Pathol. 189, 339–353. doi: 10.1016/j.ajpath.2018.10.010

Farini, A., Sitizia, C., Cassinelli, L., Colleoni, F., Parolini, D., and Giovanella, U. (2015). Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle. Development 143, 658–669. doi: 10.1242/dev.126193

Fayssoil, A., Abasse, S., and Silverston, K. (2017). Cardiac Involvement classification and therapeutic management in patients with Duchenne muscular dystrophy. J. Neurosci. Dis. 4, 17–23. doi: 10.2333/jnd-160194

Fayssoil, A., Olrikowski, D., Nardi, O., and Annane, D. (2008). Complete atrioventricular block in Duchenne muscular dystrophy. Eur. Eur. Pacing ArrhythmiasCardiac Electrophysiol. 10, 1351ñ1352.
Fayssoil, A., Orlikowskii, D., Nardi, O., and Annane, D. (2010). Pacemaker implantation for sinus node dysfunction in a young patient with duchenne muscular dystrophy. *Congest. Heart Fail. 16*, 127–128.

Fayssoil, A., Ritzenhaler, T., Luis, D., Hullin, T., Blair, C., Annane, D., et al. (2014). Be careful about abdominal discomfort in adult patients with muscular dystrophy. *Res. Neurol. 170*, 548–550. doi: 10.1016/j.neuro.2014.06.003

Ferrantini, C., Pioner, J. M., Martella, D., Coppini, R., Piroddi, N., Paolhi, P., et al. (2019). Development of light-sensitive liquid crystalline elastomers to assist cardiac contraction. *Circ. Res. 124*, e44–e54. doi: 10.1161/CIRCRESAHA.118.313889

Ferrantini, C., Pioner, J. M., Mazzoni, L., Gentile, F., Tosi, B., Rossi, A., et al. (2018). Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. *Br. J. Pharmacol. 175*, 2635–2652. doi: 10.1111/bph.14223

Frank, D., Yusuf Rangrez, A., Friedrich, C., Dittmann, S., Stallmeyer, B., Yadv, P., et al. (2019). Cardiac alpha-Actin (ACTC1) gene mutation causes atrial-septal defects associated with late-onset dilated cardiomyopathy. *Circ. Genomic Preci. Med. 12*, e002491. doi: 10.1161/CIRCGEN.119.002491

Frankel, K. A., and Rossier, R. J. (1976). The pathology of the heart in progressive muscular dystrophy: epimycocardial fibrosis. *Hum. Pathol. 7*, 375–386.

Gartz, M., Darlington, A., Afzal, M. Z., and Strande, J. L. (2018). Exosomes act as an extracellular communication module in dystrophic cardiomyocytes by ERK1/2-p38/MAPK signaling. *Sci. Rep. 8*, 16519. doi: 10.1038/s41598-018-34879-6

Gherghiceanu, M., Barad, L., Novak, A., Reiter, I., Itskovitz-Eldor, J., Binah, O., et al. (2014). Be careful about abdominal discomfort in adult patients with muscular dystrophy. *Congest. Heart Fail. 2014*. doi: 10.1093/eurheartj/ehx596

Hasselberg, N. E., Haland, T. F., Saberniak, J., Brekke, P. H., Berge, K. E., Leren, H. E., van der Heijden, J. F., Kranias, E. G., Sanoudou, D., de Boer, A. W. M., et al. (2015). Automated video-based analysis of contractility and calcium flux in human-induced pluripotent stem cell-derived cardiomyocytes cultured over different spatial scales. *Tissue Eng Part C 21*, 467–479. doi: 10.1089/ten.TEC.2014.0283

Iodice, F., Testa, G., Averardi, M., Branccaccio, G., Amodeo, A., and Cogo, P. (2015). Implantation of a left ventricular assist device as a destination therapy in Duchenne muscular dystrophy patients with end stage cardiac failure: management and lessons learned. *Neuromusc. Disord. 25*, 19–23. doi: 10.1016/j.nmd.2014.08.008

Iorga, B., Schwanken, K., Weber, N., Wendland, M., Greten, S., Piep, B., et al. (2017). Differences in contractile function of myofibris within human embryonic stem cell-derived cardiomyocytes vs. adult ventricular myofibris are related to distinct sarcomeric protein isoforms. *Front. Physiol. 8*:1111. doi: 10.3389/fphys.2017.01111

Ithzahi, I., Schiller, J., Beyar, R., Satin, J., and Gepstein, L. (2006). Calcium handling in embryonic stem cell-derived cardiac myocytes of mice and men. *Ann. N. Y. Acad. Sci. 1080*, 207–215.

Japp, A. G., Golati, A., Cook, S. A., Cowie, M. R., and Prasad, S. K., (2016). The pathology of the heart in progressive muscular dystrophy: epimycocardial fibrosis. *Hum. Pathol. 7*, 375–386.

Judge, L. M., Perez-Bermejo, A. J., Truong, A., Ribeiro, A. J., Yoo, J. C., and Jensen, C. L. (2017). A BA63 chaperone complex maintains cardomyocyte function during proteotoxic stress. *JCI Insight* 2:e94623. doi: 10.1172/jci.insight.94623

Kaprielian, R. R., and Severs, N. J. (2000). Dystrophin deficiency leads to genomic instability in human pluripotent stem cells via no synthesize-induced oxidative stress. *Cells 8*:53. doi: 10.3390/cells8100053

Koob, N., van, S., Roentgen, A. A. (2012). The chemical compound PTC124 does not affect cellular functions in embryonic stem cells. *Stem Cell Res. 12*, 467–480. doi: 10.1016/j.scr.2013.02.008

Koob, N., van, S., Roentgen, A. A. (2012). The chemical compound PTC124 does not affect cellular functions in embryonic stem cells. *Stem Cell Res. 12*, 467–480. doi: 10.1016/j.scr.2013.02.008

Koob, N., van, S., Roentgen, A. A. (2012). The chemical compound PTC124 does not affect cellular functions in embryonic stem cells. *Stem Cell Res. 12*, 467–480. doi: 10.1016/j.scr.2013.02.008

Kaprielian, R. R., and Severs, N. J. (2000). Dystrophin and the cardiomyocyte membrane cytoskeleton in the healthy and failing heart. *Heart Fail Rev. 5*, 221–238.

Kaprielian, R. R., Stevenson, S., Rothery, S. M., Cullen, M. J., and Severs, N. J. (2000). Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium. *Circulation 101*, 2586–2594.

Karayiannis, I., Stillitano, F., Nonnenmacher, M., Tzimas, C., Sanoudou, D., and Termilcgnich, V. (2015). Correction of human phospholamban R14del mutation associated with cardomyopathy using targeted nucleases and combination therapy. *Nat. Commun. 6*:6955. doi: 10.1038/ncomms7955

Klimas, A., Ambrosi, C. M., Yu, J. Z., Williams, J. C., Bien, H., and Entcheva, E. (2016). OptoDyCE as an automated system for high-throughput all-optical dynamic cardiac electrophysiology. *Nat. Commun. 7*:11542. doi: 10.1038/ncomms11542

Kofoopmann, T. V., Verkerk, A. O., Bezizna, C. R., de Bakker, J. M., and Wilde, A. A. (2012). The chemical compound PTC124 does not affect cellular electrophysiology of cardiac ventricular myocytes. *Cardiovasc. Drugs Ther. 26*, 41–45.

Kryuchenko, V., Kryuchenko, S., Tiburcy, M., Shelton, J. M., Long, C., and Schneider, J. W. (2017). Functional correction of dystrophin actin binding domain mutations by genome editing. *JCI Insight* 2:e95918. doi: 10.1172/jci.insight.95918

Le, S., Yu, M., Hovan, L., Zhao, Z., Ervasti, J., and Yan, J. (2018). Dystrophin As a Molecular Shock Absorber. *ACS Nano 12*, 12140–12148. doi: 10.1021/acsnano.8b05721

Lee, Y. K., Lau, Y. M., Cai, J. Z., Lai, W. H., Wong, L. Y., Tao, H. F., et al. (2017). Modeling treatment response for lamin A/C related dilated cardomyopathy in human induced pluripotent stem cells. *J. Am. Heart Assoc. 6*:e005677. doi: 10.1161/JAHA.117.005677

Levy-Leya, M., Sandoval, A., Felix, R., and Gonzalez-Ramirez, R. (2018). Biochemical and functional interplay between ion channels and the components of the dystrophin-associated glycoprotein complex. *J. Membr. Biol. 251*, 335–350. doi: 10.1007/s00232-018-0036-9

Li, X., Lu, W. J., Li, Y., Wu, F., Bai, R., Ma, S., et al. (2019). MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotype due to abnormal calcium handling. *Cell Death Dis. 10*:1610. doi: 10.1038/s41419-019-1826-4

Liang, W., Duan, Y. P., Shang, B. R., Wang, Y. P., Hu, C., and Lippke, S. (2019). A web-based lifestyle intervention program for Chinese college students: study
protocol and baseline characteristics of a randomized placebo-controlled trial. BMC Public Health 19:1097. doi: 10.1186/s12889-019-7438-1
Lin, B., Li, Y., Han, L., Kaplan, A. D., Ao, Y., Kalra, S., et al. (2015). Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with duchenne muscular dystrophy. Dis. Models Mech. 8, 457–466. doi: 10.1242/dmm.019905
Lipszultz, S. E., Sleeper, L. A., Towbin, J. A., Lowe, A. M., Orav, E. J., Cox, G. F., et al. (2003). The incidence of pediatric cardiomyopathy in two regions of the United States. N. Eng. J. Med. 348, 1647–1655.
Long, C., Li, H., Tiburcy, M., Rodríguez-Caycedo, C., Kyrychenko, V., and Zhou, H. (2018). Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci. Adv. 4:eaa9004. doi: 10.1126/sciadv.aag9004
Lundy, S. D., Zhu, Z. W., Regnier, M., and Laflamme, M. A., (2013). Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 22, 1991–2002. doi: 10.1089/scd.2012.0490
Macadangdang, J., Guan, X., Smith, A. S., Lucero, R., Czerniecki, S., Childers, M. K., et al. (2015). Nanopatterned Human iPSC-based model of a dystrophin-null cardiomyopathic phenotype. Cell. Mol. Bioeng. 33:5797–5804.
Mandell, J. L. (1989). Dystrophin. The gene and its product. Nature 339, 584–586.
Manning, G. W., and Cropp, G. J. (1998). The electrocardiogram in progressive muscular dystrophy. Br. Heart J. 2, 416–420.
Markham, L. W., Kinnett, K., Wong, B. L., Woodrow Benson, D., and Cripe, L. H. (2008). Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromusc. Disord. 18, 365–370.
Markham, L. W., Michelfelder, E. C., Border, W. L., Khouy, P. R., Spencer, R. L., and Wong, B. L. (2006). Abnormalities of diastolic function precede dilated cardiomyopathy associated with Duchenne muscular dystrophy. J. Am. Soc. Echocardiogr. 19, 865–871.
Maroto, R., Raso, A., Wood, T. G., Kurosky, A., Martinac, B., and Hamill, O. P. (2005). TRPC1 forms the stretch-activated cation channel in vertebrate cells. Nat. Cell Biol. 7, 179–185.
Martella, D., Paoli, P., Pioner, J. M., Sacconi, L., Coppini, R., Santini, L., et al. (2017). Liquid crystalline networks toward regenerative medicine and tissue repair. Small 13:146. doi: 10.1002/smll.201702677
Massoudi, E., Poletes, J., Mangeot, P. E., Mournetas, V., Nectoux, J., Debrugnave, N., et al. (2015). Dp421e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells. Skeletal Muscle 5:40. doi: 10.1186/s13395-015-0062-6
McNair, W. P., Sinagra, G., Carniel, E., Slavov, D., Zhu, X., Barbat, G., et al. (2013). Poor prognosis of rare sarcomeric gene variants in patients with dilated cardiomyopathy. Clin. Trans. Sci. 6, 424–428. doi: 10.1111/cts.12116
Merrick, D., Stadler, L. K., Lanfer, D., and Smith, J. (2009). Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation. Dis. Models Mech. 2, 374–388. doi: 10.1242/dmm.010018
Mertens, L., Ganame, J., Claus, P., Goemans, N., Thijis, D., and Eyskens, B. (2008). Early regional myocardial dysfunction in young patients with duchenne muscular dystrophy. J. Am. Soc. Echocardiogr. 21, 1049–1054.
Mestroni, L., Brun, F., Spezzacatene, A., Sinagra, G., and Taylor, M. R. (2014). Genetic causes of dilated cardiomyopathy. Prog. Pediatr. Cardiol. 37, 13–18.
Min, Y. L., Li, H., Rodríguez-Caycedo, C., Mireault, A. A., Huang, J., and Shelton, J. M. (2019). CRISPR-Cas9 corrects duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci. Adv. 5:eaa4324. doi: 10.1126/sciadv.a4324
Mitzelfelt, K. A., Limphong, P., Choi, M. J., Kondrat, F. D., Lai, S., and Kolander, K. D. (2016). The Human 343dET HSPB5 chaperone associated with early-onset skeletal myopathy causes defects in protein solubility. J. Biol. Chem. 291, 14939–14953. doi: 10.1074/jbc.M116.730481
Mora, M., Di Blasio, C., Barresi, R., Morandi, L., Brambati, B., Jarre, L., et al. (1996). Developmental expression of dystrophin, dystrophin-associated glycoproteins and other membrane cytoskeletal proteins in human skeletal and heart muscle. Brain Res. Dev. Brain Res. 91, 70–82.
Mora, M., Morandi, L., Merlini, L., Vita, G., Baradello, A., and Barresi, R. (1994). Fetus-like dystrophin expression and other cytoskeletal protein abnormalities in centronuclear myopathies. Muscle Nerve 17, 1176–1184.
Moreau, A., Gosselin-Badarouline, P., Mercier, A., Burger, B., Keller, D. I., and Chahine, M. (2018). A leaky voltage sensor domain of cardiac sodium channels causes arrhythmias associated with dilated cardiomyopathy. Sci. Rep. 8:13804. doi: 10.1038/s41598-018-31772-0
Moretti, A., Fonteyne, L., Giesert, F., Hoppmann, P., Meier, A. B., Bozoglu, T., et al. (2020). Somatic gene editing ameliorates cardiac muscle failure in pig and human models of duchenne muscular dystrophy. Nat. Med. 26, 207–214. doi: 10.1038/s41591-019-0738-2
Mosqueira, M., Zeiger, U., Forderer, M., Reinkemeier, H., and Fink, R. H. (2013). Cardiac and respiratory dysfunction in duchenne muscular dystrophy and the role of second messengers. Med. Res. Rev. 33, 1174–1213. doi: 10.1002/med.21279
Muntoni, F. (2003). Cardiomyopathy in muscular dystrophies. Curr. Opin. Neurol. 16, 577–583.
Muntoni, F., Torelli, S., and Ferlini, A. (2003). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet. Neurol. 2, 731–740.
Nannini, S., Re, A., Ripoli, C., Gowran, A., Nigro, P., D’Amario, D., et al. (2016). The nuclear pore protein Nup153 associates with chromatin and regulates cardiac gene expression in dystrophic mdx hearts. Cardiovasc. Res. 112, 555–567. doi: 10.1093/cvr/cvw204
Ng, R., Manning, H., Papoutsidakis, N., Alberetti, T., Tsai, N., and See, C. J. (2019). Patient mutations linked to arrhythmogenic cardiomyopathy enhance calpain-mediated desmolakin degradation. JCI Insight 5:eaav4324. doi: 10.1126/jci.insight.128643.
Nigro, G., Comi, L. I., Politano, L., and Bain, R. J. (1990). The incidence and evolution of cardiomyopathy in duchenne muscular dystrophy. Int. J. Cardiol. 26, 271–277.
Nunes, S. S., Miklas, J. W., Liu, J., R. Aschar-Sobbi, Xiao, Y., Zhang, B., et al. (2013). Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat. Methods 10, 781–787. doi: 10.1038/nmeth.2524
Ortiz-Genga, MF, Cuenca, S, Dal Ferro, M, Zorio, E, Salgado-Aranda, R, Climent, V, (2016). Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J. Am. Coll. Cardiol. 68, 2440–2451.
Perloff, J. K. (1984). Cardiac rhythm and conduction in duchenne's muscular dystrophy: a prospective study of 20 patients. J. Am. Coll. Cardiol. 3, 1263–1268.
Pioner, J. M., Guan, X., Kliman, J. M., Racca, A. W., Pabon, L., and Muskeli, V. (2019a). Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes derived from human induced pluripotent stem cells. Cardiovas. Res. 116, 368–382. doi: 10.1093/cvr/cvz109
Pioner, J. M., Santini, L., Palandrini, C., Martella, D., Lupi, F., Langione, M., et al. (2019b). Optical investigation of action potential and calcium handling...
maturation of hiPSC-Cardiomyocytes on biomimetic substrates. Int. J. Mol. Sci. 20;3799. doi: 10.3390/ijms20153799

Pioner, J. M., Racca, A. W., Klaiman, J. M., Yang, K. C., Guan, X., Pabon, L., et al. (2016). Isolation and mechanical measurements of myofibers from human induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Rep. 6, 885–896. doi: 10.1016/j.stemcr.2016.04.006

Priori, S. G., Blomstrom-Lundqvist, C., Mazzanti, A., Blom, N., Borggreve, M., Camm, J., et al. (2015). 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 36, 2793–2867.

Racca, A. W., Klaiman, J. M., Pioner, J. M., Cheng, Y., Beck, A. E., Moussavi-Rahimov, F., and Kunkel, L. M. (2013). The cell biology of disease: cellular maturation of hiPSC-Cardiomyocytes on biomimetic substrates. Eur. Heart J. 36, 2793–2867.

Shafqatullah, S., Li, Y. Y., Lin, E., Stevens, C. M., Dewar, L. J., and Lynn, F. C. (2019). In vitro analyses of suspected arrhythmogenic thin filament variants as a cause of sudden cardiac death in infants. Proc. Natl. Acad. Sci. U.S.A. 116, 6969–6974. doi: 10.1073/pnas.1819023116

Shah, D., Virtanen, L., Prapajati, C., Kämmer, M., Gullmets, J., West, G., et al. (2019). Modeling of LMNA-related dilated cardiomyopathy using induced pluripotent stem cell models. Cells 8:594.

Shahneen, N., Shit, A., Huber, I., Shinnawi, R., Arbel, G., and Gepstein, A. (2018). Human induced pluripotent stem cell-derived cardiac cell sheets expressing genetically encoded voltage indicator for pharmacological and arrhythmia studies. Stem Cell Rep. 10, 1879–1894. doi: 10.1016/j.stemcr.2018.04.006

Shimojima, M., Yusa, S., Motoda, C., Yozu, N., Nagai, T., Ito, S., et al. (2017). Emerin plays a crucial role in nuclear invagination and in the nuclear calcium transient. Sci. Rep. 7, 44312. doi: 10.1038/srep44312

Shirokova, N., and Niggl, E. (2013). Cardiac phenotype of Duchenne muscular dystrophy: insights from cellular studies. J. Mol. Cell. Cardiol. 58, 217–224. doi: 10.1016/j.yjmcc.2012.12.009

Silva, M. C., Magalhaes, T. A., Meira, Z. M., Rassi, C. H., Andrade, A. C., Kihara, N., et al. (2017). Myocardial fibrosis progression in Duchenne and Becker muscular dystrophy: a randomized clinical trial. JAMA Cardiol. 2, 190–199.

Song, Y., Chen, W., Li, D., Wang, H., Liao, W., Eddleman, K., et al. (2015). The K219T-Lamin mutation induces conduction defects through Reversal of mitochondrial fragmentation in iPSC-derived cardiomyocytes from patients with duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 113, 932–938. doi: 10.1073/pnas.1516543113

Sun, N., Azawa, M., Liu, J., Han, L., Sanchez-Freire, V., and Abilez, O. J. (2020). High incidence of electrocardiogram abnormalities in young patients with duchenne muscular dystrophy. Pediatr. Neurol. 87, 1854–1865. doi: 10.1016/j.pediatrneurol.2020.08.006

Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 131, 823–833. doi: 10.1016/j.cell.2007.10.045

Tardiff, J. C., Carrier, L., Bers, D. M., Poggesi, C., and Coppini, R. (2015). Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc. Res. 105, 457–470. doi: 10.1093/cvr/cvy023

Taylor, M. R., Slavoff, D., Li, K., Lenarda, A. Di, Sinagra, G., Carniel, E., et al. (2007). Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 115, 1244–1251.

Towbin, J. A., Heijman, J. F., Brink, P., Gelb, B., Zhu, X. M., Chamberlain, J. S., et al. (1993). X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 87, 1854–1865.
van der Zwaag, P. A., van Rijsingen, I. A., Asimaki, A., Jongbloed, J. D., Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M., Weber, N., Schwanke, K., Greten, S., Wendland, M., Iorga, B., Fischer, M., Wang, M., Birnkrant, D. J., Super, D. M., Jacobs, I. B., and Bahler, R. C. (2018).

Wang, L., Kim, K., Parikh, S., Cadar, A. G., Bersell, K. R., He, H., et al. (2014). Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the phenotypic pathogens of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. *Hum. Mol. Genet.* 22, 1395–1403. doi: 10.1093/hmg/ddv556

Tsurumi, F., Baba, S., Yoshinaga, D., Umeda, K., Hirata, T., Takita, J., et al. (2019). The intracellular Ca2+ concentration is elevated in cardiomyocytes differentiated from hiPSCs derived from a Duchenne muscular dystrophy patient. *PloS One* 14:e0213768. doi: 10.1371/journal.pone.0213768

Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M., Hauch, K. D., et al. (2011). Growth of engineered human myocardium with mechanical loading and vascular coculture. *Circ. Res.* 109, 47–59. doi: 10.1161/CIRCRESAHA.110.237206

Ulmer, B. M., and Eschenhagen, T., (2019). Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism. *Biodım. Biophys. Acta. Mol. Cell Res.* 1867: 118471 doi: 10.1016/j.bbamcr.2019.04.001

van den Berg, C. W., Okawa, S., Chua de Sousa Lopes, S. M., van Iperen, L., Passier, R., Braam, S. R., et al. (2015). Transcriptome of human foetal heart compared with cardiomyocytes from pluripotent stem cells. *Development* 142, 3231–3238. doi: 10.1242/dev.123810

van der Zwaag, P. A., van Rijssing, I. A., Asimaki, A., Jongbloed, J. D., van Veldhuisen, D. J., Wiesfeld, A. C., et al. (2012). Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy: an in vitro analysis from an RMB20 patient-derived iPSC model. *Clin. Transl. Sci.* 9, 158–167. doi: 10.1111/cts.12393

Vyas, S. P., Li, X., Hrstka, S. C., Reyes, S., Terzic, A., Olson, T. M., and Nelson, T. J. (2016a). Pharmacological modulation of calcium homeostasis in familial dilated cardiomyopathy: an in vitro analysis from an RMB20 patient-derived iPSC model. *Hum. Mol. Genet.* 25, 254–265. doi: 10.1093/hmg/ddv468

Yasuda, S., Townsend, D., Michele, D. E., Favre, E. G., Day, S. M., and Metzger, J. M. (2005). Dystrophic heart failure blocked by membrane sealant poloxamer. *Nature* 436, 1025–1029.

Yermakovitch, D., Sivitskaya, I., Vaikhamskaya, T., Danilenko, N., and Motuk, I. (2018). Novel desmoplakin mutations in familial cardiac syndrome. *Acta Myol.* 7, 263–266.

Young, C. S., Hicks, M. R., Ermolova, N. V., Nakano, H., Jan, M., Younesi, S., et al. (2016). A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. *Cell Stem Cell* 18, 533–540. doi: 10.1016/j.stem.2016.01.021

Zatti, S., Martewicz, S., Serena, E., Uno, N., Giobbe, G., Kazuki, Y., et al. (2014). Complete restoration of multiple dystrophin isoforms in genetically corrected Duchenne muscular dystrophy patient-derived cardiomyocytes. *Mol. Ther. Methods Clin. Dev.* 1:1. doi: 10.1038/mtm.2013.1

Zaunbrecher, R. J., Abel, A. N., Beusman, K., Leonard, A., von Frielig-Salewsky, M., Fields, P. A., et al. (2019). Crumos tin is expressed in human cardiomyocytes and necessary for normal sarcomere function. *Circulation* 140, 1647–1660.

Zhan, H., Stanciauskas, R., Stigloher, C., Dizon, K. K., Jospin, M., Bessereau, J. L., et al. (2014). In vivo single-molecule imaging identifies altered dynamics of calcium channels in dystrophin-mutant C. elegans. *Nat. Commun.* 5:4974. doi: 10.1038/ncomms5974

Zhang, Y., Long, C., Li, H., McNally, J. R., Baskin, K. K., and Shelton, J. M. (2017). CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice. *Sci. Adv.* 3:e1602814. doi: 10.1126/sciadv.1602814

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Pioneer, Fornaro, Coppini, Ceschia, Sacconi, Donati, Favilli, Poggesi, Olivotto and Ferrantini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.